ArticlePloS one2011
Serodiversity of opsonic antibodies against Enterococcus faecalis--glycans of the cell wall revisited.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Cell surface polysaccharides in the gut microbiota: occurrence, structure and role.Gut microbes · 2025Review
- Trivalent immunization with metal-binding proteins confers protection against enterococci in a mouse infection model.FEMS microbes · 2024Article
- Enterococcal Membrane Vesicles as Vaccine Candidates.International journal of molecular sciences · 2023Article
- Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.Chemical reviews · 2022Review
- Intrinsic resistance of Enterococcus faecalis strains to ΦEf11 phage endolysin is associated with the presence of ΦEf11 prophage.Archives of virology · 2021Article
- Review
- Article
- Conjugation of Different Immunogenic Enterococcal Vaccine Target Antigens Leads to Extended Strain Coverage.The Journal of infectious diseases · 2019Article
- Detection and characterization of bacterial polysaccharides in drug-resistant enterococci.Glycoconjugate journal · 2019Article
- Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci.Infection and immunity · 2019Article
- A Vaccine Approach for the Prevention of Infections by Multidrug-resistant Enterococcus faecium.The Journal of biological chemistry · 2015Article
- In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens.Infection · 2015Article
- Isolation of highly active monoclonal antibodies against multiresistant gram-positive bacteria.PloS one · 2015Article
- Characterization of Two Metal Binding Lipoproteins as Vaccine Candidates for Enterococcal Infections.PloS one · 2015Article
- Mechanisms of antibiotic resistance in enterococci.Expert review of anti-infective therapy · 2014Review
- Molecular characterization of Rifr mutations in Enterococcus faecalis and Enterococcus faecium.Journal of chemotherapy (Florence, Italy) · 2014Article
- Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations.Infection · 2014Article
- Identification of peptidoglycan-associated proteins as vaccine candidates for enterococcal infections.PloS one · 2014Article
- Article
- A novel role for D-alanylation of lipoteichoic acid of enterococcus faecalis in urinary tract infection.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a typing system based on opsonic antibodies against carbohydrate antigens of the cell envelope, 60% of Enterococcus faecalis strains can be assigned to one of four serotypes (CPS-A to CPS-D). The structural basis for enterococcal serotypes, however, is still incompletely understood. Here we demonstrate that antibodies raised against lipoteichoic acid (LTA) from a CPS-A strain are opsonic to both CPS-A and CPS-B strains. LTA-specific antibodies also bind to LTA of CPS-C and CPS-D strains, but fail to opsonize them. From CPS-C and CPS-D strains resistant to opsonization by anti-LTA, we purified a novel diheteroglycan with a repeating unit of →6)-β-Galf-(1→3)- β-D-Glcp-(1→ with O-acetylation in position 5 and lactic acid substitution at position 3 of the Galf residue. The purified diheteroglycan, but not LTA absorbed opsonic antibodies from whole cell antiserum against E. faecalis type 2 (a CPS-C strain) and type 5 (CPS-D). Rabbit antiserum raised against purified diheteroglycan opsonized CPS-C and CPS-D strains and passive protection with diheteroglycan-specific antiserum reduced bacterial counts by 1.4-3.4 logs in mice infected with E. faecalis strains of the CPS-C and CPS-D serotype. Diheteroglycan-specific opsonic antibodies were absorbed by whole bacterial cells of E. faecalis FA2-2 (CPS-C) but not by its isogenic acapsular cpsI-mutant and on native PAGE purified diheteroglycan co-migrated with the gene product of the cps-locus, suggesting that it is synthesized by this locus. In summary, two polysaccharide antigens, LTA and a novel diheteroglycan, are targets of opsonic antibodies against typeable E. faecalis strains. These cell-wall associated polymers are promising candidates for active and passive vaccination and add to our armamentarium to fight this important nosocomial pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.